• US: +1-408-610-2300
  • Toll Free: +1-866-831-4085
  • Login / Register
Scleroderma Diagnostics and Therapeutics Market Size Report, 2018

Scleroderma Diagnostics and Therapeutics Industry 2018 Market Research Report

Report ID: MN17615425  |  Published: August 2017  |  No of Pages: 113
Format: Electronic (PDF)  |  Industry: Therapeutic Area  |  Publisher: QY Research

Global Scleroderma Diagnostics and Therapeutics Market is expected to grow at a significant CAGR in the upcoming years as the scope and its applications are rising enormously across the globe. Scleroderma is also termed as systemic sclerosis (SSc), is a chronic, autoimmune disease characterized by structural and functional abnormalities of production of autoantibodies, small blood vessels, and fibrosis of the skin and internal organs. The diagnosis of scleroderma is based on the clinical appearances of the illness. Whereas, treatment is directed toward the individual features affecting different areas of the body.

Scleroderma Diagnostics and Therapeutics Market is segmented based on types, drug types, diagnosis, and region. Types such as Systemic Scleroderma (Limited Scleroderma and Diffused Scleroderma) and Localized Scleroderma (Linear Scleroderma and Morphea) classify Scleroderma Diagnostics and Therapeutics Market. Drug types such as Prostacyclin Analogues, Corticosteroids, Chelating Agents, Immunosuppressive Agents, PDE-5 Inhibitors, Endothelin Receptor Agonists, Calcium Channel Blockers, and others (ACE Inhibitors, H2 Blockers, and Proton Pump Inhibitors) classify Scleroderma Diagnostics and Therapeutics Market.

Diagnosis of Pulmonary Function Tests, Skin Viscoelasticity, Electrocardiogram and Echocardiogram, Imaging Techniques, Blood Tests/ Antibodies Tests, Capillaroscopy, and Cardiac Diagnosis classify Scleroderma Diagnostics and Therapeutics Market. The market is segmented geographically Americas (North America, Latin America), Europe (Eastern Europe, Western Europe), Asia Pacific, Latin America, Middle East and Africa.

Globally, North America accounts for the largest market share of Scleroderma Diagnostics and Therapeutics Market and is estimated to lead the overall market in the upcoming years. The reason being, government initiative and funding programs coupled with key manufacturers, enhanced research and development sectors, and presence of an extensive number of clinical trials. Europe and Asia Pacific follow suit.

Europe is the second largest region accounting overall market share of Scleroderma Diagnostics and Therapeutics Industry. On the other hand, Asia Pacific is estimated to grow at fastest pace in the upcoming years. The reason being, the presence of unmet patient needs and the subsequent rise in usage rates.

The key players of Scleroderma Diagnostics and Therapeutics Market are Merck KGaA, Actelion Pharmaceuticals Inc., F. Hoffmann La Roche Ltd., Boehringer Ingelheim, Corbus Pharmaceutical Holdings Inc., Bayer AG, Sanofi, Cytori Therapeutics Inc., Pfizer Inc., Cumberland Pharmaceuticals Inc., and Gilead Sciences Inc. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.

Market Segment:

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Scleroderma Diagnostics and Therapeutics in these regions, from 2013 to 2025 (forecast), covering
• North America
• Europe
• China
• Japan
• Southeast Asia
• India

Global Scleroderma Diagnostics and Therapeutics market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• Actelion Pharmaceuticals, Inc.
• Boehringer Ingelheim
• Bayer AG
• Cytori Therapeutics, Inc.
• Cumberland Pharmaceuticals Inc
• Gilead Sciences, Inc.
• Pfizer, Inc.
• Sanofi
• Corbus Pharmaceutical Holdings, Inc.
• F. Hoffmann La Roche Ltd.
• Merck KGaA

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• Corticosteroids
• Immunosuppressive Agents
• Endothelin Receptor Agonists
• Calcium Channel Blockers
• PDE-5 Inhibitors
• Chelating Agents
• Prostacyclin Analogues
• Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.)

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
• Skin Biopsy
• Imaging Techniques
• Blood Tests
• Electrocardiogram and Echocardiogram
• Pulmonary Function Tests

What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service
  • 100% Secure Payments
  • Our Promise
  • 100% Service Assurance
  • Market Monitoring
  • Service Flexibility
  • 24X5 Care available